Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Phenylethylmalonamide in essential tremor. A double-blind controlled study

S Calzetti, L J Findley, F Pisani

    Journal of Neurology, Neurosurgery, and Psychiatry
    |October 1, 1981
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Influence of cytotoxic T-lymphocyte antigen-4 polymorphisms on acute rejection onset of cadaveric renal transplants.

    Transplantation proceedings·2013
    Same author

    For anti-HLA-specific donor antibodies detection by flow cytometry cytotoxic crossmatches comparison of methods.

    Transplantation proceedings·2013
    Same author

    Impact of generic substitution of anticonvulsants on the treatment of epilepsy.

    CNS drugs·2013
    Same author

    Cytomegalovirus and gastric cancer after renal transplantation: a possible interplay.

    Transplantation proceedings·2012
    Same author

    Management of kidney transplantation in a factor VII-deficient patient: case report.

    Transplantation proceedings·2012
    Same author

    Evolution of bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma and Waldenstrom's macroglobulinemia: a retrospective multicentric study.

    Blood cancer journal·2012

    Phenylethylmalonamide, a primidone metabolite, showed no significant effect in treating essential tremor patients. This randomized controlled trial found no improvement in tremor amplitude or patient-reported outcomes.

    Area of Science:

    • Neurology
    • Pharmacology
    • Clinical Trials

    Background:

    • Essential tremor (ET) is a common neurological disorder.
    • Primidone is used to treat essential tremor, and phenylethylmalonamide is its primary metabolite.
    • The efficacy of phenylethylmalonamide alone for essential tremor has not been established.

    Purpose of the Study:

    • To evaluate the efficacy of phenylethylmalonamide in patients with essential tremor.
    • To assess the safety and tolerability of phenylethylmalonamide in this patient population.

    Main Methods:

    • A randomized, double-blind, placebo-controlled trial was conducted.
    • Eight patients with essential tremor received phenylethylmalonamide at 400 mg/day for one week, followed by 800 mg/day for a second week.
    • Tremor amplitude was assessed using accelerometry, performance tests, clinical evaluation, and patient self-assessment.

    Related Experiment Videos

    Main Results:

    • Phenylethylmalonamide did not produce a statistically significant reduction in tremor amplitude.
    • No significant improvements were observed in performance tests, clinical evaluations, or patient self-assessments.
    • No adverse side effects were reported during the trial.

    Conclusions:

    • Phenylethylmalonamide, at the tested doses, is not effective in treating essential tremor.
    • Further research may be needed to explore other potential therapeutic roles or optimal dosing strategies for phenylethylmalonamide.